Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
SUM149PT Tivantinib
0.031623
MET
RTK
 0.9878 0.00138
SUM149PT Tivantinib
0.1
MET
RTK
 0.9462 0.01839
SUM149PT Tivantinib
0.31623
MET
RTK
 0.3961 0.23223
SUM149PT Tivantinib
1.0
MET
RTK
 -0.1122 0.46281
SUM149PT Tivantinib
3.1623
MET
RTK
 -0.2088 0.46613
SUM149PT Tivantinib
10.0
MET
RTK
 -0.2313 0.47870
SUM149PT Cediranib
0.001
VEGFR/cKIT
RTK
 1.0057 0.00393
SUM149PT Cediranib
0.0031623
VEGFR/cKIT
RTK
 1.0538 0.00067
SUM149PT Cediranib
0.01
VEGFR/cKIT
RTK
 1.0195 0.00280
SUM149PT Cediranib
0.031623
VEGFR/cKIT
RTK
 1.0209 -0.00375
SUM149PT Cediranib
0.1
VEGFR/cKIT
RTK
 1.0429 -0.00212
SUM149PT Cediranib
0.31623
VEGFR/cKIT
RTK
 1.0948 -0.00545
SUM149PT Cediranib
1.0
VEGFR/cKIT
RTK
 0.9902 -0.00136
SUM149PT Cediranib
3.1623
VEGFR/cKIT
RTK
 0.8489 0.00214
SUM149PT Cediranib
10.0
VEGFR/cKIT
RTK
 0.0656 0.23935
SUM149PT Cabozantinib
0.001
VEGFR2/MET
RTK
 0.9965 -0.00008
SUM149PT Cabozantinib
0.0031623
VEGFR2/MET
RTK
 1.0250 0.00441
SUM149PT Cabozantinib
0.01
VEGFR2/MET
RTK
 1.0291 0.00184
SUM149PT Cabozantinib
0.031623
VEGFR2/MET
RTK
 1.0217 0.00043
SUM149PT Cabozantinib
0.1
VEGFR2/MET
RTK
 1.0323 0.00185
SUM149PT Cabozantinib
0.31623
VEGFR2/MET
RTK
 1.0133 0.00194
SUM149PT Cabozantinib
1.0
VEGFR2/MET
RTK
 1.0082 0.00549
SUM149PT Cabozantinib
3.1623
VEGFR2/MET
RTK
 0.9208 0.01403
SUM149PT Cabozantinib
10.0
VEGFR2/MET
RTK
 0.2895 0.14842
T47D Abemaciclib
0.001
CDK4/6
Cell cycle
 0.8683 -0.00073